Orig3n, a US-based developer of treatments for rare, inherited genetic diseases, has completed a $12.5m series A round featuring genomic testing company LabCorp.
Hatteras Venture Partners and Syno Capital co-led the round, which also included venture capital firms Defta Partners, Harris & Harris Group, MGC Venture Partners and KTB, the latter of which invested through its KTB-Korus Fund.
The series A round will fund the launch of cellular models based on the LifeCapsule bio-repository established by Orig3n earlier this year. The company claims it is the largest bank of induced pluripotent stem cells in the world.
Orig3n previously raised $3.1m from KTB, Harris & Harris, Defta and MGC in February 2015.
Robin Y. Smith, chief executive of Orig3n, said: “The continued support of our existing investors and the confidence of our new investors will enable us to accelerate the growth of Orig3n.
“We are developing some innovative science and business models that enable researchers to develop safer and more effective drugs and lay down the foundations for regenerative medicine treatments.”